To test whether the reduction in cell viability of BRCA2-deficient cells upon TPX2 depletion was also observed in other cancer models, we engineered four other breast cancer cell lines with doxycycline-inducible BRCA2 shRNAs: SUM149-shBRCA2dox, MDA-MB231-shBRCA2dox, HCC38-shBRCA2dox, and HCC1806-shBRCA2dox. The gene discussed is TPX2; the disease is cancer.